Dextroamphetamine_Sulfate: profile and news

Dangers of stimulant abuse Feb 1, 2006
In April 2005, a University of Oregon student was arrested for selling legally obtained Adderall and dextroamphetamine sulfate out of his dorm room. ... - University Daily Kansan,

Functional Neuroanatomical Substrates of Altered Reward Processing ... Nov 8, 2005
...in MDD, using functional magnetic resonance imaging in combination with a dopaminergic probe (a 30-mg dose of oral dextroamphetamine sulfate) to stimulate the ... - Archives of General Psychiatry

Clearing the Fog Oct 10, 2005
...system stimulant, is composed of four amphetamine salts: amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate and dextroamphetamine sulfate ... - The UCSD Guardian Online

Student arrested for selling prescription drugs Apr 12, 2005
Police determined that he had been reselling legally obtained amphetamine in the form of Adderall and dextroamphetamine sulfate, drugs commonly used to treat ... - Oregon Daily Emerald

UO student charged with selling speed Apr 12, 2005
...teen's room. Investigating officers determined that Kling had valid prescriptions for Adderall and dextroamphetamine sulfate. The ... - The Register-Guard,

Other information

Indication
For treatment of Attention Deficit Disorder with Hyperactivity (ADDH) and narcolepsy in children.

Pharmacology
Amphetamine and dextroamphetamine, non-catechloamine sypathomimetic agents, are used in combination to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy. Adderall consists of equivalent amounts of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate.

Mechanism Of Action
Amphetamine and dextroamphetamine stimulate the release of norepinephrine from central adrenergic receptors. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect.

Drug Category
Adrenergic Agents; Dopamine Agents; Dopamine Uptake Inhibitors; Adrenergic Uptake Inhibitors; Central Nervous System Stimulants; Amphetamines; Sympathomimetics; ATC:N06BA01

Brand Names/Synonyms
Actedron; Adipan; Allodene; Amphetamine; Amphetamine Sulfate; Anorexide; Anorexine; Benzebar; Benzedrine; Benzolone; Desoxyn; Dexampex; Dexedrine; Dextroamphetamine Sulfate; Dextrostat; Elastonon; Fenamin; Fenylo-izopropylaminyl; Ferndex; Finam; Isoamycin; Isoamyne; Isomyn; Mecodrin; Methampex; Methamphetamine HCL; Norephedrane; Norephedrine, deoxy-; Novydrine; Oktedrin; Ortedrine; Paredrine; Percomon; Phenamine; Phenedrine; Phenylisopropylamine; Profamina; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Simpatina; Sympamin; Sympamine; Sympatedrine; Weckamine; amphetamine base; dl-Amphetamine; dl-Benzedrine; m-Methoxyamphetamine; alpha-Methylbenzeneethaneamine; beta-Aminopropylbenzene; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; 1-Methyl-2-phenylethylamine; 1-Phenyl-2-aminopropane; 3-Methoxy-a-methylbenzeneethanamine; 3-Methoxyamphetamine; 3-Methoxyphenylisopropylamine; Amphetamine (Narcotics); DL-alpha-Methylphenethylamine; [1-(3-Methoxyphenyl)-2-propyl]amine; dl-1-Phenyl-2-aminopropane; m-Methoxy-a-methylphenethylamine; racemic-Desoxynor-ephedrine

Dosage Forms
tablets combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextroisomer of amphetamine saccharate and 6, I-amphetamine aspartate.

Absorption
It forms easily absorbed molecules that are highly lipid soluble

Interactions
Acidifying agents - Gastrointestinal acidifying agents (guanethidine,reserpine, glutamic acid HCl,ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents -(ammonium chloride, sodium acid phosphate, etc.) Increase the concentration of the ionized species of the amphetamine. Primary excretion - Both Groups of agents lower blood levels and efficacy of amphetamines. Adrenergic blockers - Adrenergic blockers are inhibited by amphetamines. Alkalinizing agents -Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.)increase absorption of amphetamines. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentate the actions of amphetamines. Antidepressants, tricyclic - Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. MAO inhibitors - MAO antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings, this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results. Antihistamines - Amphetamines may counteract the sedative effect of antihistamines. Antihypertensives - Amphetamines may antagonize the hypotensive effects of antihypertensives. Chlorpromazine - Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning. Ethosuximide - Amphetamines may delay intestinal absorption of ethosuximide. Haloperidol - Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines. Lithium carbonate - The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate. Meperidine - Amphetamines pone the analgesic effect of meperidine. Methenamine therapy - Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy. Norepinephrine - Amphetamines enhance the adrenergic effect of norepinephrine. Phenobarbital - Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action. Phenytoin - Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action. Propoxyphene - In cases of propoxyphene overdose, amphetamine CNS stimulation is potentiated and fatal convulsions can occur. Veratrum alkaloids - Amphetamines inhibit the hypotensive effect of veratrum alkaloids. Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.

Chemical IUPAC Name
1-phenylpropan-2-amine

Chemical Formula
C9H13N

Half Life
10 hours

Drug Type
Approved Drug

# Accession No
APRD00480

CAS Registry Number
300-62-9